NEW YORK (360Dx) – Qiagen announced today that the US Food and Drug Administration approved the company's test for assessing the risk of spontaneous preterm birth in patients with preterm labor symptoms.

PartoSure includes a noninvasive strip test that detects placental alpha microglobulin in patients. It provides results in five minutes or less, and, said Qiagen, studies have demonstrated that, compared with current diagnostic methods, the test has a higher positive predictive value for preterm birth while maintaining an equally high negative predictive value.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Sponsored by

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.